Associate Chief Physician, MD. Specialties: Has long‑term clinical experience in medical treatment for thoracic malignancies. Specializes in the diagnosis and management of thoracic tumors (including non‑small‑cell lung cancer, small‑cell lung cancer, malignant pleural mesothelioma, thymic carcinoma, etc.), with particular focus on individualized treatment and whole‑course management of lung cancer, covering chemotherapy, targeted therapy, immunotherapy and clinical application of novel agents, and keeps abreast of the latest international advances in this field. Graduated from China Medical University in 2005 with a Master’s degree in Clinical Medicine. Has been practicing at Peking University Cancer Hospital since August 2005. Earned a Doctoral degree in Clinical Oncology from Peking University Cancer Hospital from 2013 to 2016. Has participated in multiple international and domestic multicenter clinical trials, some of whose findings have updated NCCN and CSCO guidelines. Has published numerous papers in SCI‑indexed and core journals. Among them, the abstract of Immune‑Related Adverse Events and Their Association With the Effectiveness of PD‑1/PD‑L1 Inhibitors in Non‑Small Cell Lung Cancer: A Real‑World Study From China (Frontiers in Oncology. 2021; 11(607531)) was accepted for Poster Presentation at the World Conference on Lung Cancer (WCLC). The paper Multivariate Prognostic Analysis of 160 Elderly Patients with Small‑Cell Lung Cancer (Chinese Journal of Lung Cancer. 2014;17(01):15‑23) won the Second Prize at the 6th Chinese Geriatric Oncology Society (CGOS) Annual Conference.